Figure 4

Flowcytometry cell cycle pattern analysis of HepG2 cancer cells. Treatments were as follows: sorafenib (I), bevacizumab (II), panitumumab (III), ramucirumab¹², sorafenib-bevacizumab combination (V), sorafenib-panitumumab combination (VI), sorafenib-ramucirumab (VII) and untreated (control) HepG2 cancer cells (VIII).